{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:28:51Z","timestamp":1785767331681,"version":"3.56.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with recurrent or metastatic head and neck squamous cell carcinoma (R\/M-HNSCC) face poor prognosis. This study evaluated the efficacy and safety of a novel first-line regimen combining tislelizumab, nab-paclitaxel, carboplatin, and cetuximab (TPCE) in R\/M-HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, 39 patients with R\/M-HNSCC received tislelizumab (200 mg, day 1), nab-paclitaxel (125 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , days 1, 8), carboplatin (AUC = 2, days 1, 8), and cetuximab (400 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      loading dose, then 250 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      weekly, day 1) every 21 days for up to six cycles. Patients achieving stable disease or better continued maintenance therapy with cetuximab and tislelizumab until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The TPCE regimen demonstrated significant antitumor activity, with an ORR of 82.1% and a DCR of 97.4%. With a median follow-up of 27.0 months (95% confidence interval [CI]: 23.6-30.4 months), the median DOR was 12.5 months (95% CI: 9.5-15.5 months), the median PFS was 14.0 months (95% CI: 11.0-17.1 months), and the median OS was 27.0 months (95% CI: 20.7-33.3 months). The 2-year PFS rate was 31.3 \u00b1 7.8%, and the 2-year OS rate was 58.4 \u00b1 8.4%. Subgroup analysis revealed a significantly higher ORR in patients with tongue carcinoma (P = 0.023). Lower baseline neutrophil-to-lymphocyte ratio (NLR, P = 0.044), systemic immune-inflammation index (SII, P = 0.044), and albumin level (P = 0.044) were correlated with improved ORR. A reduction in NLR after two treatment cycles was also associated with higher ORR (P = 0.037). Multivariate analysis identified baseline hemoglobin-albumin-lymphocyte-platelet (HALP) score as an independent prognostic factor for PFS (HR: 2.919; 95% CI: 1.153-7.391; P = 0.024), while primary tumor location (HR: 3.160; 95% CI: 1.205-8.282; P = 0.019), HALP score (HR: 3.541; 95% CI: 1.287-9.744; P = 0.014), and post-treatment SII changes (HR: 0.370; 95% CI: 0.151-0.906; P = 0.030) were independent predictors for OS. Grade 3\u20134 treatment-emergent adverse events were primarily hematologic, with granulocytopenia (38.5%) being the most common. Most immune-related adverse events were grade 1-2, with hypothyroidism (33.3%) occurring most frequently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TPCE regimen demonstrated robust antitumor efficacy and a manageable safety profile as a first-line treatment for R\/M-HNSCC. Baseline and dynamic inflammatory-nutritional markers may serve as predictive and prognostic indicators, supporting clinical decision-making for this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>http:\/\/www.chictr.org.cn<\/jats:ext-link>\n                      , identifier ChiCTR2500108877.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1708410","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:36:29Z","timestamp":1767940589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhanyong","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boran","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangling","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci11020042","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12885-024-12155-3","article-title":"Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis","volume":"24","author":"Cirillo","year":"2024","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq588","article-title":"Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: EXTREME study","volume":"22","author":"Licitra","year":"2011","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30755-5","article-title":"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014\u201301 TPExtreme): a multicentre, open-label, randomized, phase 2 trial","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0333","article-title":"Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients","volume":"5","author":"Jie","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomized, multicenter, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3849","article-title":"Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Chung","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.06.09","article-title":"Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study","volume":"36","author":"Gui","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.2096-7993.2023.10.003","article-title":"Tislelizumab monotherapy for the treatment of recurrent\/metastatic head and neck squamous cell carcinoma","volume":"37","author":"Song","year":"2023","journal-title":"Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e2532512","DOI":"10.1001\/jamanetworkopen.2025.32512","article-title":"Improving the reporting on health equity in observational research (STROBE-equity): extension checklist and elaboration","volume":"8","author":"Dewidar","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001133","article-title":"Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma","volume":"37","author":"Gauduchon","year":"2025","journal-title":"Curr Opin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2362612","article-title":"Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives","volume":"20","author":"Gatfield","year":"2024","journal-title":"Future Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"115395","DOI":"10.1016\/j.ejca.2025.115395","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study","volume":"221","author":"Tahara","year":"2025","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26331","article-title":"Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator\u2019s choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)","volume":"42","author":"Yen","year":"2020","journal-title":"Head Neck"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/antib9020017","article-title":"Combined anti-cancer strategies based on anti-checkpoint inhibitor antibodies","volume":"9","author":"Golay","year":"2020","journal-title":"Antib (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3886","article-title":"Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, nonrandomized, phase II clinical trial","volume":"29","author":"Gulati","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02625","article-title":"Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): A single-arm phase IV trial","volume":"42","author":"Dzienis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e009034","DOI":"10.1136\/jitc-2024-009034","article-title":"Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies","volume":"12","author":"Zhang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf045","article-title":"Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox","volume":"30","author":"Ottaiano","year":"2025","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1557652","article-title":"Neutrophil\/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors","volume":"15","author":"Caterino","year":"2025","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11206","DOI":"10.1038\/s41598-024-84469-y","article-title":"Peripheral inflammatory factors as prognostic predictors for first-line PD-1\/PD-L1 inhibitors in advanced non-small cell lung cancer","volume":"15","author":"Jin","year":"2025","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12957-024-03522-2","article-title":"Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"22","author":"Chiu","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10238-025-01675-2","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictive biomarkers for treatment response in primary advanced hypopharyngeal squamous cell carcinoma treated with chemoimmunotherapy","volume":"25","author":"Shi","year":"2025","journal-title":"Clin Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-192","article-title":"Retrospective study on the prognostic prediction of inflammatory markers and the C-reactive protein\/albumin ratio in first-line immunotherapy for advanced HER2 negative gastric cancer patients","volume":"14","author":"Sun","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.06.039","article-title":"First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomized, phase III CHANGE-2 trial","volume":"156","author":"Guo","year":"2021","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12957-024-03644-7","article-title":"The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study","volume":"23","author":"Ouyang","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13951","article-title":"Application and perspectives of immunotherapy in head and neck squamous cell carcinoma","volume":"176","author":"Zhang","year":"2025","journal-title":"Immunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2451079","article-title":"The association between HALP score and survival in patients treated with immune checkpoint inhibitors","volume":"25","author":"Sahin","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e42261","DOI":"10.1097\/MD.0000000000042261","article-title":"The prognostic value of HALP score in predicting the efficacy of nivolumab treatment in metastatic Malignant melanoma patients: A real-life, retrospective, single center analysis","volume":"104","author":"Ata","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jds.2025.04.026","article-title":"Exploring gender-specific prognostic factors and survival outcomes in oral squamous cell carcinoma: Insights from a Taiwanese cohort","volume":"20","author":"Ko","year":"2025","journal-title":"J Dent Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12885-023-11064-1","article-title":"Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters","volume":"23","author":"Jia","year":"2023","journal-title":"BMC Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15964","article-title":"Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy","volume":"114","author":"Huai","year":"2023","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1602290","article-title":"Early-life undernutrition, immune dysregulation, and cancer incidence in later life: a national life-course analysis from the China health and retirement longitudinal study","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"105173","DOI":"10.1016\/j.oraloncology.2020.105173","article-title":"Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial","volume":"115","author":"Adkins","year":"2021","journal-title":"Oral Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708410\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:36:31Z","timestamp":1767940591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1708410\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2025.1708410"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1708410","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1708410"}}